Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.
Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H
+
-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin.
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats.
Animal Model:
Mice bearing MCF-7 or A431 xenografts
Dosage:
200 mg/kg
Administration:
IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
Result:
Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin.
There is no effect on growth delay alone.
